Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma.

Background: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.

Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.

Results: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival.

From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma.

Multiple Myeloma (MM) is a complex hematological malignancy characterized by the clonal proliferation of malignant plasma cells within bone marrow (BM) [...

Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First-Line Treatment.

The purpose of the study was to investigate the effects of exercise training on the bone marrow immune microenvironment and on minimal residual disease of multiple myeloma patients who completed first-line induction treatment. Eight multiple myeloma patients underwent 5 months of exercise training along with standard medical treatment. Eight age- and sex-matched patients who received medical treatment only, served as controls.